In this episode, we explore Carthera, a French biotech company developing novel ultrasound-based technologies to improve drug delivery to the brain. Based in Paris and spun out from academic research, Carthera is best known for its implantable device, SonoCloud, which uses low-intensity pulsed ultrasound to temporarily open the blood-brain barrier. This allows for increased drug penetration into brain tumors, addressing one of the major challenges in treating diseases like glioblastoma.

This episode features leadership and key collaborators from Carthera, including CEO Frédéric Sottilini, who shares how his background in therapeutic ultrasound and medical device development helped guide the company’s path from concept to clinical trials. We are also joined by Professor Alexandre Carpentier, MD, PhD, the neurosurgeon who founded Carthera, and Michael Vogelbaum, MD, PhD, Chief of Neurosurgery at Moffitt Cancer Center, who offers his perspective as a clinical investigator working with the company’s technology.

This episode offers insight into the intersection of engineering, neurosurgery, and translational research, and the collaborative effort required to develop new treatment tools for brain tumor patients.

Learn more at https://carthera.eu/

This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.